Skip to main
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is a commercial-stage MedTech company with a promising product, the ASSURE Cardiac Recovery System, which has received FDA approval and is gaining market share in the rapidly growing WCD market. The company's expanding salesforce, positive real-world data, and strategic collaborations position it well for further revenue acceleration and gross margin expansion. Risks to our Buy rating and $32 price target include commercial execution, regulatory and reimbursement decisions, efforts to improve profitability, competition, and balance sheet.

Bears say

Kestra Medical Techs is a relatively new company that has received FDA approval for its ASSURE Cardiac Recovery System. However, its stock should be approached with caution due to its limited financial history and the potential for market competition. It is also worth noting that while the company's revenue and margin have been steadily increasing, it may take a while for new sales representatives to reach full productivity and for the company to drive further improvements in its conversion rate.

KMTS has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 4 analysts, KMTS has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.